Our ‘Research In Practice’ profiles bring you original content - from interviews and posts, to exciting and interactive live events focused on latest trends and findings in translational medicine.


This September,  ‘Research in Practice in Cancer’ presents a 3-part series on ‘T Cells and Cancer’. Join our first episode on 2nd September at 10am BST / 9am Dr Vivian Dimou, The Institute of Cancer Research. Sign up here to receive email reminders for this series.


What are we going to talk about in this episode?


In this session, we will address a number of important questions:


  • Why are T cells such an important immune cell population for fighting cancer?


  • How can translational research on patient clinical samples help scientists elucidate the immune phenotype of T cells - and can such work drive cancer research forward?


  • What techniques are used for immunological research such as T cell immunophenotyping?


  • And finally, how T cells have been leveraged to develop novel, highly efficacious immunotherapies? 


Series programme:


  • 2nd September, 10am BST / 9am GMT - ‘T cell immunological research at the forefront of defeating cancer’ with Dr Vivian Dimou,  The Institute of Cancer Research 


  • 13th September, 1pm BST / 12 pm GMT - ‘Activation of Neoantigen Specific T cells for the Treatment of Solid Tumors’ with Prof Karine Breckpot Vrije Universiteit Brussel


  • 22nd September, 1pm BST / 12 pm GMT - ‘Engineering T-cells for the Treatment of Solid Tumours’ with Dr Ben Draper,  UCL   


Please follow Researcher Live’s profile ‘Research In Practice in Cancer’ for interview content, relevant posts, and future event series!



If you'd like to present at your own Researcher Live event, please email kristine.lennie@researcher-app.com 

Date and Time
Friday, September 2, 2022
10:00 am BST/ 09:00 am GMT
Speakers Avatar Dr Vivian Dimou, The Institute of Cancer Research

Dr Vivian Dimou completed her undergraduate degree in Molecular Biology & Genetics in Greece in 2014 before moving to the UK, where she obtained a PhD in Autoimmunity and childhood lupus nephritis, at the University of Liverpool (2015-2018). She's always had a keen interest in Immunology and, since her PhD, has become even more fascinated by the complex and intricate functions of different immune cell populations, and especially the T cells. In 2018, she moved to London for her first postdoc at St George’s University of London. There, she worked on immunophenotyping blood samples from patients with acute coronary syndrome and atrial fibrillation, to investigate potential deregulations in the function of T cell populations. Since March 2020, she has been working at the Institute of Cancer Research, Sutton, as a Postdoctoral Training Fellow in Dr Astero Klampatsa’s Thoracic Oncology Immunotherapy Group.

Vivin's postdoctoral research project is focused on exploring the mesothelioma immune landscape, and especially the role of T cells, NK cells and dendritic cells, via multi-colour flow cytometry, using paired, patient-derived blood and tumour tissue samples.

She is aiming to perform an in-depth study of the immunophenotype of innate and adaptive immune cells important for anti-tumour immunity, link these findings with patient responses to immunotherapies and identify novel immunotherapeutic targets. 

DOI: HfnflPmaWoUEm6Og04iA_prepost_3

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.